CN113896711A - 杂环类免疫调节剂 - Google Patents

杂环类免疫调节剂 Download PDF

Info

Publication number
CN113896711A
CN113896711A CN202010633550.2A CN202010633550A CN113896711A CN 113896711 A CN113896711 A CN 113896711A CN 202010633550 A CN202010633550 A CN 202010633550A CN 113896711 A CN113896711 A CN 113896711A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010633550.2A
Other languages
English (en)
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Priority to CN202010633550.2A priority Critical patent/CN113896711A/zh
Priority to MX2023000382A priority patent/MX2023000382A/es
Priority to CA3189041A priority patent/CA3189041A1/en
Priority to PCT/CN2021/102873 priority patent/WO2022007659A1/zh
Priority to KR1020237004029A priority patent/KR20230037035A/ko
Priority to EP21838438.6A priority patent/EP4177247A4/en
Priority to AU2021303635A priority patent/AU2021303635A1/en
Priority to US18/014,623 priority patent/US20230271933A1/en
Priority to CN202180048474.1A priority patent/CN115776983A/zh
Priority to JP2023500425A priority patent/JP7712703B2/ja
Publication of CN113896711A publication Critical patent/CN113896711A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202010633550.2A 2020-07-06 2020-07-06 杂环类免疫调节剂 Pending CN113896711A (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202010633550.2A CN113896711A (zh) 2020-07-06 2020-07-06 杂环类免疫调节剂
MX2023000382A MX2023000382A (es) 2020-07-06 2021-06-28 Inmunomoduladores heterocíclicos.
CA3189041A CA3189041A1 (en) 2020-07-06 2021-06-28 Heterocyclic immunomodulators
PCT/CN2021/102873 WO2022007659A1 (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂
KR1020237004029A KR20230037035A (ko) 2020-07-06 2021-06-28 헤테로시클릭 면역조정제
EP21838438.6A EP4177247A4 (en) 2020-07-06 2021-06-28 HETEROCYCLIC IMMUNOMODULATOR
AU2021303635A AU2021303635A1 (en) 2020-07-06 2021-06-28 Heterocyclic immunomodulator
US18/014,623 US20230271933A1 (en) 2020-07-06 2021-06-28 Heterocyclic immunomodulator
CN202180048474.1A CN115776983A (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂
JP2023500425A JP7712703B2 (ja) 2020-07-06 2021-06-28 ヘテロ環式免疫調節物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010633550.2A CN113896711A (zh) 2020-07-06 2020-07-06 杂环类免疫调节剂

Publications (1)

Publication Number Publication Date
CN113896711A true CN113896711A (zh) 2022-01-07

Family

ID=79186707

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010633550.2A Pending CN113896711A (zh) 2020-07-06 2020-07-06 杂环类免疫调节剂
CN202180048474.1A Pending CN115776983A (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180048474.1A Pending CN115776983A (zh) 2020-07-06 2021-06-28 杂环类免疫调节剂

Country Status (9)

Country Link
US (1) US20230271933A1 (https=)
EP (1) EP4177247A4 (https=)
JP (1) JP7712703B2 (https=)
KR (1) KR20230037035A (https=)
CN (2) CN113896711A (https=)
AU (1) AU2021303635A1 (https=)
CA (1) CA3189041A1 (https=)
MX (1) MX2023000382A (https=)
WO (1) WO2022007659A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222614A1 (zh) * 2023-04-28 2024-10-31 北京诺诚健华医药科技有限公司 杂环类gspt1降解剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3202460T3 (pl) * 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
CA3108974C (en) 2012-08-09 2023-04-04 Celgene Corporation Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof
WO2014116573A1 (en) * 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
NZ731789A (en) * 2014-10-30 2019-04-26 Kangpu Biopharmaceuticals Ltd Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
ES2963446T3 (es) * 2015-09-29 2024-03-27 Kangpu Biopharmaceuticals Ltd Composición farmacéutica y aplicación de la misma
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
WO2018140671A1 (en) * 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2018351050B2 (en) * 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
CN107739389B (zh) 2017-11-03 2020-03-31 华东师范大学 3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法
KR102718800B1 (ko) * 2018-05-23 2024-10-18 셀진 코포레이션 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
CA3106239A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
WO2020210630A1 (en) * 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222614A1 (zh) * 2023-04-28 2024-10-31 北京诺诚健华医药科技有限公司 杂环类gspt1降解剂

Also Published As

Publication number Publication date
MX2023000382A (es) 2023-04-18
US20230271933A1 (en) 2023-08-31
KR20230037035A (ko) 2023-03-15
AU2021303635A1 (en) 2023-02-09
CN115776983A (zh) 2023-03-10
CA3189041A1 (en) 2022-01-13
EP4177247A1 (en) 2023-05-10
EP4177247A4 (en) 2024-08-07
JP7712703B2 (ja) 2025-07-24
JP2023533003A (ja) 2023-08-01
WO2022007659A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7716110B2 (ja) ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用
CN111225896B (zh) 免疫调节剂化合物
CN118005656B (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
JP7712703B2 (ja) ヘテロ環式免疫調節物質
CN107735399B (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
CN109843873B (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
JP6402179B2 (ja) 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体
WO2021023233A1 (zh) Egfr蛋白降解剂及其抗肿瘤应用
CN112745298B (zh) 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
CN115141215A (zh) Kras g12d蛋白抑制剂和其用途
EP3878852A1 (en) Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
CN102421771B (zh) 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
KR20240019071A (ko) N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법
CN121311477A (zh) 内酰胺类衍生物及其应用
KR20240024060A (ko) 인테그린 억제제에 대한 확장된 투여량 요법
TW202227441A (zh) 喹唑啉化合物、包含其的藥物組合物及其應用
WO2024217481A1 (zh) Egfr降解剂、其药物组合物及其用途
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
WO2025035759A1 (zh) 一种kif18a抑制剂及其用途
KR20250154490A (ko) 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도
WO2025256655A1 (zh) 一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
CN115417868A (zh) 一种具有抗肿瘤活性的杂环化合物及其用途
EP4288417A1 (en) Substituted pyrazolyl compounds as malt-1 inhibitors
EA047485B1 (ru) Соединение, представляющее собой средство для разрушения белка, и его применения для лечения рака и предупреждения или лечения болезни кеннеди

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220107